Evaluation of human neutrophil peptide-1, -2 and -3 as serum markers for colorectal cancer

Cancer Biomarkers

Volumn 7, Issue 2, 2010, Pages 109-115

  Van Den Broek, Irene ^a   Sparidans, Rolf W ^a   Engwegen, Judith Y M N ^b   Cats, Annemieke ^c   Depla, Annekatrien C T M ^d   Schellens, Jan H M ^a,c   Beijnen, Jos H ^a,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

colorectal cancer; Human neutrophil peptides; LC MS MS; serum markers

Indexed keywords

DEFENSIN 1; DEFENSIN 2; DEFENSIN 3; POLYPEPTIDE ANTIBIOTIC AGENT; TUMOR MARKER; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER SURGERY; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; TANDEM MASS SPECTROMETRY; UPREGULATION;

AGED; ALPHA-DEFENSINS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLONOSCOPY; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 78650588696     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2010-0153     Document Type: Article

References (28)

1. World Health Organziation, Fact sheet on cancer, http://www. who.int/mediacentre/factsheets/fs297/en/index.html, (February 2009).
2. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu and M.J. Thun, Cancer statistics, 2009, CA Cancer J Clin 59(4) (2009), 225-249.
3. J.P. Heiken, Screening for colon cancer, Cancer Imaging 6 (2006), S13-21.
4. S.D. Markowitz and M.M. Bertagnolli, Molecular origins of cancer: Molecular basis of colorectal cancer, N Engl J Med 361(25) (2009), 2449-2460.
5. J. Weitz, M. Koch, J. Debus, T. Hohler, P.R. Galle and M.W. Buchler, Colorectal cancer, Lancet 365(9454) (2005), 153-165.
6. A. Umar and S. Srivastava, The promise of biomarkers in colorectal cancer detection, Dis Markers 20(2) (2004), 87-96. (Pubitemid 39149917)
7. M.J. Duffy, A. van Dalen, C. Haglund, L. Hansson, E. HolinskiFeder, R. Klapdor, R. Lamerz, P. Peltomaki, C. Sturgeon and O. Topolcan, Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use, Eur J Cancer 43(9) (2007), 1348-1360.
8. M.J. Duffy, Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 47(4) (2001), 624-630.
9. J. Albrethsen, R. Bogebo, S.Gammeltoft, J. Olsen, B.Winther and H. Raskov, Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study, BMC Cancer 5 (2005), 8.
10. J. Albrethsen, C.H. Moller, J. Olsen, H. Raskov and S. Gammeltoft, Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer, Eur J Cancer 42(17) (2006), 3057-3064.
11. S. Kanmura, H. Uto, M. Numata, S. Hashimoto, A. Moriuchi, H. Fujita,M.Oketani, A. Ido,M.Kodama, H.Ohi andH. Tsubouchi, Human neutrophil peptides 13 are useful biomarkers in patients with active ulcerative colitis, Inflamm Bowel Dis 15(6) (2009), 909-917.
12. C. Melle, G. Ernst, B. Schimmel, A. Bleul, H. Thieme, R. Kaufmann, H.Mothes, U. Settmacher, U. Claussen, K.J.Halbhuber and F. Von Eggeling, Discovery and identification of alphadefensins as low abundant, tumorderived serum markers in colorectal cancer. Gastroenterology 129(1) (2005), 66-73.
13. T. Ganz and R.I. Lehrer, Defensins, Curr Opin Immunol 6(4) (1994), 584-589.
14. J. Ashitani, H. Mukae, Y. Arimura, A. Sano, M. Tokojima and M. Nakazato, High concentrations of alphadefensins in plasma and bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome, Life Sci 75(9) (2004), 1123-1134.
15. J. Ashitani, H. Mukae, T. Hiratsuka, M. Nakazato, K. Kumamoto and S. Matsukura, Elevated levels of alphadefensins in plasma and BAL fluid of patients with active pulmonary tuberculosis, Chest 121(2) (2002), 519-526.
16. T. Ihi, M. Nakazato, H. Mukae and S. Matsukura, Elevated concentrations of human neutrophil peptides in plasma, blood, and body fluids from patients with infections, Clin Infect Dis 25(5) (1997), 1134-1140.
17. H. Mukae, H. Iiboshi, M. Nakazato, T. Hiratsuka, M. Tokojima, K.Abe, J.Ashitani, J.Kadota, S.Matsukura and S.Kohno, Raised plasma concentrations of alphadefensins in patients with idiopathic pulmonary fibrosis, Thorax 57(7) (2002), 623-628.
18. K. Shiomi, M. Nakazato, T. Ihi, K. Kangawa, H. Matsuo, and S. Matsukura, Establishment of radioimmunoassay for human neutrophil peptides and their increases in plasma and neutrophil in infection, Biochem Biophys Res Commun 195(3) (1993), 1336-1344.
19. N. Yamaguchi, H. Isomoto, H. Mukae, H. Ishimoto, K. Ohnita, S. Shikuwa, Y. Mizuta, M. Nakazato and S. Kohno, Concentrations of alphaand betadefensins in plasma of patients with inflammatory bowel disease, Inflamm Res 58(4) (2009), 192-197.
20. I. Van den Broek, R.W. Sparidans, J.H.M. Schellens and J.H. Beijnen, Validation of a quantitative assay for human neutrophil peptides1, 2, and 3 in human plasma and serum by liquid chromatography coupled to tandem mass spectrometry, J Chromatogr B Analyt Technol Biomed Life Sci 878(15-16) (2010), 1085-1092.
21. http://www.fda.gov/cder/guidance/4252fnl.htm, Guidance for industry: Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CEDR), Center for Veterinary Medicine (CVM), BP, May 2001.
22. N. Droin, J.B. Hendra, P. Ducoroy and E. Solary, Human defensins as cancer biomarkers and antitumour molecules, J Proteomics 72(6) (2009), 918-927.
23. H.Mothes, C. Melle, G. Ernst, R. Kaufmann, F. von Eggeling and U. Settmacher, Human Neutrophil Peptides 13- early markers in development of colorectal adenomas and carcinomas, Dis Markers 25(2) (2008), 123-129.
24. R.I. Lehrer, T. Ganz andM.E. Selsted, Defensins: endogenous antibiotic peptides of animal cells, Cell 64(2) (1991), 229-230.
25. H. Mukae, H. Ishimoto, S. Yanagi, H. Ishii, S. Nakayama, J. Ashitani, M. Nakazato and S. Kohno, Elevated BALF concentrations of alphaand betadefensins in patients with pulmonary alveolar proteinosis, Respir Med 101(4) (2007), 715-721.
26. Y. Mohri, T. Mohri, W. Wei, Y.J. Qi, A. Martin, C. Miki, M. Kusunoki, D.G. Ward and P.J. Johnson, Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer, Br J Cancer 101(2) (2009), 295-302.
27. A.V. Panyutich, E.A. Panyutich, V.A. Krapivin, E.A. Baturevich and T. Ganz, Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis, J Lab Clin Med 122(2) (1993), 202-207.
28. J.Y. Engwegen, A.C.Depla,M.E. Smits,A. Cats, H. Tuynman, H.A. van Heukelem, P. Snel,W.Meuleman, L.F.Wessels, J.H. Schellens and J.H. Beijnen, Detection of Colorectal Cancer by Serum and Tissue Protein Profiling: A Prospective Study in a Population at Risk, Biomark Insights 3 (2008), 375-385.